FDA Advisory Panel Recommends Approval for Replimune Melanoma Therapy

By Ed Silverman · STAT News · 2026-07-31

STAT News reports that an FDA advisory committee voted 10-to-3 in favor of Replimune’s RP1, an engineered viral immunotherapy for advanced melanoma. The recommendation follows two prior rejections for the drug, indicating a potential shift in how regulators evaluate investigation

STAT News reports that an FDA advisory committee voted 10-to-3 in favor of Replimune’s RP1, an engineered viral immunotherapy for advanced melanoma. The recommendation follows two prior rejections for the drug, indicating a potential shift in how regulators evaluate investigation